Andera Partners’s Evommune Inc EVMN Stock Holding History

Andera Partners’s Portfolio EVMN Stock Details EVMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.6M	Hold	1,897,362	–	–	24.66%	2
2025 Q4	$32.5M	Buy	+1,897,362	New	+$35.6M	18.39%	3

Other funds holding EVMN

EQT Fund Management Luxembourg $1.02B AUM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Andera Partners's EVMN Position: Q1 2026 in Review

Andera Partners held its Evommune Inc (EVMN) position steady in Q1 2026 at 1,897,362 shares worth $43.6M. The position accounts for 24.66% of the portfolio, ranked #2.

Andera Partners first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

Andera Partners held 1,897,362 shares of Evommune Inc worth $43.6M as of Q1 2026.
Andera Partners left its Evommune Inc share count unchanged in Q1 2026.
Evommune Inc made up 24.66% of Andera Partners's portfolio in Q1 2026, its #2 holding.
Andera Partners first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Andera Partners's 13F filing for Q1 2026, filed 11 May 2026.